Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: A retrospective chart review in Japanese patients

Clinical Therapeutics

Volumn 32, Issue 1, 2010, Pages 24-33

  Ishii, Hideki ^b   Kumada, Yoshitake ^b   Toriyama, Takanobu ^b   Aoyama, Toru ^b   Takahashi, Hiroshi ^b   Tanaka, Miho ^b   Kamoi, Daisuke ^b   Kawamura, Yoshihiro ^b   Yamada, Shigeki ^b   Hayashi, Mutsuharu ^a   Yasuda, Yoshinari ^a   Yuzawa, Yukio ^a   Maruyama, Shoichi ^a   Matsuo, Seiichi ^a   Matsubara, Tatsuaki ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kaikoukai Nagoya Kyoritsu Hospital   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

cilostazol; hemodialysis; percutaneous transluminal angioplasty; peripheral artery disease; prognosis

Indexed keywords

CILOSTAZOL; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

AGED; ARTICLE; ASIAN; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FEMALE; FEMORAL ARTERY; FOLLOW UP; HUMAN; JAPAN; MALE; MEDICAL RECORD; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; POPLITEAL ARTERY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MATCHED-PAIR ANALYSIS; MEDICAL RECORDS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; POPLITEAL ARTERY; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

MLCS; MLOWN;

EID: 77952314157     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.01.007     Document Type: Review

References (29)

1. O'Hare, A, Johansen, K, Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 12 (2001), 2838–2847.
2. Belch, JJ, Topol, EJ, Agnelli, G, et al., Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: A call to action. Arch Intern Med. 163 (2003), 884–892.
3. Criqui, MH, Langer, RD, Fronek, A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 326 (1992), 381–386.
4. Rajagopalan, S, Dellegrottaglie, S, Furniss, AL, et al. Peripheral arterial disease in patients with end-stage renal disease: Observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 114 (2006), 1914–1922.
5. Kumada, Y, Aoyama, T, Ishii, H, et al. Long-term outcome of percutaneous transluminal angioplasty in chronic haemodialysis patients with peripheral arterial disease. Nephrol Dial Transplant. 23 (2008), 3996–4001.
6. Graziani, L, Silvestro, A, Bertone, V, et al. Percutaneous transluminal angioplasty is feasible and effective in patients on chronic dialysis with severe peripheral artery disease. Nephrol Dial Transplant. 22 (2007), 1144–1149.
7. Jaar, BG, Astor, BC, Berns, JS, Powe, NR, Predictors of amputation and survival following lower extremity revascularization in hemodialysis patients. Kidney Int. 65 (2004), 613–620.
8. O'Hare, AM, Sidawy, AN, Feinglass, J, et al. Influence of renal insufficiency on limb loss and mortality after initial lower extremity surgical revascularization. J Vasc Surg. 39 (2004), 709–716.
9. Johnston, KW, Femoral and popliteal arteries: Reanalysis of results of balloon angioplasty. Radiology. 183 (1992), 767–771.
10. Minar, E, Pokrajac, B, Maca, T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation. 102 (2000), 2694–2699.
11. Ikeda, Y, Sudo, T, Kimura, Y, Cilostazol. Platelets. 2 (2006), 1181–1191.
12. Pratt, CM, Analysis of the cilostazol safety database. Am J Cardiol. 87:Suppl (2001), 28D–33D.
13. lida, O, Nanto, S, Uematsu, M, et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J. 69 (2005), 1256–1259.
14. World Medical Association (WMA). Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/index.html Accessed December 29, 2009.
15. Norgren, L, Hiatt, WR, Dormandy, JA, et al., TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 45:Suppl S (2007), S5–S67.
16. Luellen, JK, Shadish, WR, Clark, MH, Propensity scores: An introduction and experimental test. Eval Rev. 29 (2005), 530–558.
17. Nakazawa, G, Tanabe, K, Aoki, J, et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimuseluting stents. Catheter Cardiovasc Interv. 69 (2007), 808–814.
18. Aoyama, T, Ishii, H, Toriyama, T, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J. 72 (2008), 56–60.
19. Ishii, H, Kumada, K, Toriyama, T, et al. Aortic valvular calscification predicts restenosis after implantation of drugeluting stents in patients on chronic haemodialysis. Nephrol Dial Transplant. 24 (2009), 1562–1567.
20. Lee, SW, Park, SW, Hong, MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis. J Am Coll Cardiol. 46 (2005), 1833–1837.
21. Takahashi, S, Oida, K, Fujiwara, R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20 (1992), 900–906.
22. Ikeda, Y, Kikuchi, M, Murakami, H, Comparison of the inhibitory effects of cilostazol, acetylsalicylic and ticlopidine on platelet functions ex vivo. Randomized, double-blind cross-over study. Arzneimittelforschung. 37 (1987), 563–566.
23. Tanaka, T, Ishikawa, T, Hagiwara, M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology. 36 (1988), 313–320.
24. Kamishirado, H, Inoue, T, Mizoguchi, K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J. 144 (2002), 303–308.
25. Iida, O, Nanto, S, Uematsu, M, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 48 (2008), 144–149.
26. Ishii, H, Kumada, Y, Toriyama, T, et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol. 3 (2008), 1034–1040.
27. Tsuchikane, E, Fukuhara, A, Kobayashi, T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 100 (1999), 21–26.
28. Douglas, JS Jr, Holmes, DR Jr, Kereiakes, DJ, et al., Cilostazol for Restenosis Trial (CREST) Investigators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 112 (2005), 2826–2832.
29. Lee, SW, Park, SW, Kim, YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus. The DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 51 (2008), 1181–1187.